Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

By K. Flaherty, J. Infante, A. Daud, R. Gonzalez, R. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim and 16 more. New England Journal of Medicine, 2012

2,686 citations recorded by the source corpus.

BACKGROUND Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor. METHODS In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy. The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response. Secondary end points were overall survival and pharmacokinetic activity. RESULTS Dose-limiting toxic effects were infrequently observed in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2). Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%). Median progression-free survival in the combination 150/2 group was 9.4 months, as compared with 5.8 months in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001). The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03). CONCLUSIONS Dabrafenib and trametinib were safely combined at full monotherapy doses. The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced. Progression-free survival was significantly improved. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01072175.)

Subfields: Epidemiology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/11fcdad1f9f8b6b3573c238bca21eed07f7766ea

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Molecular Biology

In Oncology

Citations in the corpus

Immune Checkpoint Blockade in Cancer Therapy. (2015, background): “Although irAEs are different in character from adverse events caused by traditional chemotherapy or targeted therapy, the rate of grade 3 or 4 toxicity with immune checkpoint blockade (approximately 10% to 20%) is no greater than that seen with many standard chemotherapy or targeted therapy regimens”
The MAPK pathway across different malignancies: A new perspective (2014, background): “The combination of dabrafenib (a BRAF kinase inhibitor) with trametinib (an MEK inhibitor) caused keratoacanthomas in 7% of patients along with rare squamous cell skin cancers compared with a frequency of 19% for dabrafenib alone.(60) This safer combination is now under evaluation in numerous other ”
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response (2015, background): “(26) across six indications in the PCTs”
Machine learning and feature selection for drug response prediction in precision oncology applications (2018, background): “…for the few known examples of cancer types that are driven by single somatic aberrations, such as BCR-ABL-positive chronic myeloid leukemia, non-small cell lung cancer or BRAF in melanoma, with clinically actionable small-molecule inhibitors available (Flaherty et al. 2012; Pemovska et al. 2015).”
Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “BRAF somatic mutation, particularly BRAF V600E/K, drive tumorigenesis through constitutive activation of the downstream MAPK pathway [198].”
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. (2014, neutral): “Any adverse event 21 (9) 70 (29) 117 (49) 22 (9) 19 (7) 66 (26) 125 (49) 34 (13)”
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies (2023, background): “331,337,521 However, the rapid development of drug resistance has limited the use of these drugs in cancer therapy, resulting in temporary bene ﬁ ts lasting from several months to less than 2 years.”
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model (2015, background): “These scoring methods are thus non-symmetric since the range of synergy is between 0 and 1, which is much smaller than the range of antagonism which is [1, ∞ ].”
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy (2014, neutral): “…of MEK and BRAF inhibitors appears to be efficacious with a favorable toxicity profile, and the Cancer Cell 25, 91–101, January 13, 2014 ª2014 Elsevier Inc. 97 combination appears to abrogate the paradoxical activation of the MAP kinase pathway in BRAF-wild-type cells (Flaherty et al., 2012).”
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways (2017, background): “Two direct inhibitors of MEK, trametinib and cobimetinib, have been approved by the FDA for melanoma treatment [416,417].”